Volumes and Outcomes

BRTI - Baylor Regional Transplant Institute

Liver Graft Survival Rates

Liver Patient Survival Rates

****Data based upon July, 2009 SRTR reports on www.ustransplant.org. 1 year time period – 01/01/2006, 3- year time period – 7/01/2003 – 12/31/2005***

Research & Clinical Trials

Baylor Research Institute

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study To Assess the Safety and Efficacy of Alefacept in De Novo Kidney Transplant Recipients

Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress

A Phase II Trial To Assess the Safety of Immunosuppression Withdrawal In Liver Transplant Recipients

Diagnostic and Therapeutic Development for Infectious Diseases

Evaluation of HepaGam B®in Combination with Antiviral Treatment in Hepatitis B Liver Transplant Patients

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation, Part A

A 24 Month Multi-Center Randomized, Open Label Study to Evaluate the Efficacy and Safety of Concentration Controlled Everolimus with Corticosteroids in Combination with Minimization or Elimination of Tacrolimus in de novo Liver Transplant Recipients Compared to Tacrolimus and Corticosteroids